Quality of life (QOL) among patients (pts) with HER2+ breast cancer (bc) treated with adjuvant lapatinib and/or trastuzumab in the ALTTO study (BIG 2-06, Alliance N063D).
Amylou C. Dueck
No relevant relationships to disclose
David W. Hillman
No relevant relationships to disclose
Lisa A. Kottschade
Consultant or Advisory Role - Genentech
Michele Y. Halyard
No relevant relationships to disclose
Jeff A. Sloan
No relevant relationships to disclose
Lynn M. Flickinger
No relevant relationships to disclose
Antonio C. Wolff
No relevant relationships to disclose
Lyndsay Harris
No relevant relationships to disclose
Julie Gralow
Research Funding - Amgen; Genentech; Novartis; Roche
Kathleen I. Pritchard
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche
Expert Testimony - Roche
Susan Ellard
No relevant relationships to disclose
Nguyet Le-Lindqwister
No relevant relationships to disclose
Frances M. Boyle
Honoraria - GlaxoSmithKline
Research Funding - GlaxoSmithKline
Evandro De Azambuja
Consultant or Advisory Role - GlaxoSmithKline
Honoraria - Roche
Research Funding - GlaxoSmithKline
Other Remuneration - GlaxoSmithKline; Roche
Worta J. McCaskill-Stevens
No relevant relationships to disclose
Jo Anne Zujewski
No relevant relationships to disclose
Martine J. Piccart-Gebhart
Consultant or Advisory Role - PharmaMar
Honoraria - Amgen; Astellas Pharma; AstraZeneca; Bayer; Invivis; Lilly; MSD; Novartis; Pfizer; Roche/Genentech; Sanofi ; Symphogen; Synthon; Verastem
Edith A. Perez
No relevant relationships to disclose